Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation

Journal of Clinical Pathology

Volumn 52, Issue 10, 1999, Pages 735-738

  Bailey, E ^a   Bottomley, M J ^b   Westwell, S ^d   Pringle, J H ^c   Furness, P N ^e   Fechally, J ^a   Brenchley, P E C ^b   Harper, S J ^d  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e NONE

Author keywords

Glomerulonephritis; Proteinuria; Vascular endothelial growth factor; Vascular permeability factor

Indexed keywords

MESSENGER RNA; VASCULOTROPIN;

AMINO ACID URINE LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GENE EXPRESSION; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; KIDNEY DISEASE; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; PROTEINURIA;

EID: 0032888010     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.10.735     Document Type: Article

References (14)

1. Williams JD, Coles GA. Proteinuria-a direct cause of renal morbidity. Kidney Int 1994;45:443-50.
2. Simon E, Gröne H-J, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268:240-50.
3. Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992;42:1457-61.
4. 125I] VEGF binding sites. J Am Soc Nephrol 1998;9:1032-44.
5. Senger DR, Connelly DT, Van de Water L, et al. Purification and N-terminal amino acid sequence of guinea-pig tumor-secreted vascular permeability factor. Cancer Res 1990;50:1774-8.
6. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-79.
7. Gröne H-J. Angiogenesis and vascular encothelial growth factor (VEGF): is it relevant in renal patients. Nephrol Dial Transplant 1995:10:761-3.
8. Pringle JH; Ruprai AK, Primrose L, et al. In situ hybridisation of immunoglobulin light chain mRNA in paraffin sections using biotinylated or hapten-labelled oligonucleotide probes. J Pathol 1990;162:197-207.
9. Harper SJ, Bailey E, McKeen C, et al. A comparative study of digoxigenin, 2,4-dinitrophenyl and alkaline phosphatase as deoxyoligonucleotide labels in non-isotopic in situ hybridisation. J Clin Pathol 1997;50:686-90.
10. Jones PH, Harper SJ, Watts F. Stem cell patterning and fate in human epidermis. Cell 1995;80:83-93.
11. Shulman K, Rosen S, Tognazzi K, et al Expression of vascular permeability (VPF/VEGF) is altered in many glomcrular diseases. J Am Soc Nephrol 1995;7:661-6.
12. Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor. Endoer Rev 1997;18:4-25.
13. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial-growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-14.
14. Poltorak Z, Cohen T, Sivan R, et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997;272:7151-8.